Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control

  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Berdasco, Maria|||0000-0002-6750-0400
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Ganoza, C.
  • Sanchez, Jorge
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Calle, M. Luz|||0000-0001-9334-415X
  • Sánchez, Alex|||0000-0002-8673-7737
  • Esteller, M.|||0000-0003-4490-6093
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
GWAS, immune analyses and biomarker screenings have identified host factors associated with in vivo HIV-1 control. However, there is a gap in the knowledge about the mechanisms that regulate the expression of such host factors. Here, we aimed to assess DNA methylation impact on host genome in natural HIV-1 control. To this end, whole DNA methylome in 70 untreated HIV-1 infected individuals with either high (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial

  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Marszalek, Marta
  • Coll, Pep
  • Manzardo, Christian
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Miró, José M.|||0000-0001-8057-7755
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4 + T cells from HIV-1 + individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited. In order to address whether the in vitro observations are replicated in vivo, we determined the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clinical trial (NCT02616874). BCN02 was a proof-of-concept study in 15 early treated HIV-1 + individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent. Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells. Although RMD reduced the number of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8 + T cells was preserved over the RMD treatment. These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Berdasco, Maria|||0000-0002-6750-0400
  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Gonçalves, Elena
  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Tolstrup, Martin
  • Søgaard, Ole S.
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Combadiere, Behazine|||0000-0002-2353-4406
  • Paredes, Roger|||0000-0002-6553-691X
  • Hartigan-O'Connor, Dennis
  • Esteller, M.|||0000-0003-4490-6093
  • Meulbroek, Michael
  • Calle, M. Luz|||0000-0001-9334-415X
  • Sánchez, Alex|||0000-0002-8673-7737
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination

  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Prats, Anna|||0000-0002-3586-4525
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Ballana, Ester|||0000-0002-5215-7363
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Hanke, Thomas
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
Biomarkers predicting the outcome of HIV-1 virus control in natural infection and after therapeutic interventions in HIV-1 cure trials remain poorly defined. The BCN02 trial (NCT02616874), combined a T-cell vaccine with romidepsin (RMD), a cancer-drug that was used to promote HIV-1 latency reversal and which has also been shown to have beneficial effects on neurofunction. We conducted longitudinal plasma proteomics analyses in trial participants to define biomarkers associated with virus control during monitored antiretroviral pause (MAP) and to identify novel therapeutic targets that can improve future cure strategies. BCN02 was a phase I, open-label, single-arm clinical trial in early-treated, HIV infected individuals. Longitudinal plasma proteomes were analyzed in 11 BCN02 participants, including 8 participants that showed a rapid HIV-1 plasma rebound during a monitored antiretroviral pause (MAP-NC, 'non-controllers') and 3 that remained off ART with sustained plasma viremia <2000 copies/ml (MAP-C, 'controllers'). Inflammatory and neurological proteomes in plasma were evaluated and integration data analysis (viral and neurocognitive parameters) was performed. Validation studies were conducted in a cohort of untreated HIV-1+ individuals (n = 96) and in vitro viral replication assays using an anti-CD33 antibody were used for functional validation.